This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.
A multicentre observational study, ctDNA aims to provide the evidence base for metatstatic disease being caused by vascular methods of spread by determining if there is a link between EMVI status and ctDNA
Study Type
OBSERVATIONAL
Enrollment
100
Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
Queen Elizabeth the Queen Mother Hospital
Margate, Kent, United Kingdom
RECRUITINGSt Mary's Hospital (Imperial)
Hammersmith, London, United Kingdom
RECRUITINGRoyal Marsden Hospital NHS Foundation Trust
Sutton, Surrey, United Kingdom
RECRUITINGTo determine if there is a link between EMVI status and ctDNA
Proportion of patients who are EMVI positive demonstrating higher % mutation frequency of circulating cell-free and tumour specific DNA compared with patients who are EMVI negative.
Time frame: Up to 2 years
To investigate whether ctDNA levels change during surgery according to EMVI status
Measure the intraoperative % mutation frequency of ctDNA in EMVI positive compared with EMVI negative patients
Time frame: Up to 2 years
To investigate the effect of ctDNA status on patient survival outcomes
Record survival outcomes of patients who are: EMVI negative with low ctDNA levels, EMVI negative with high ctDNA levels, EMVI positive with low ctDNA levels, EMVI positive with high ctDNA levels
Time frame: At 1, 2 and 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.